Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/12/21 13:22:28」(JST)

wiki en

GLP-1 and DPP-4 inhibitors

Incretins are a group of gastrointestinal hormones that stimulate a decrease in blood glucose levels. Incretins do so by causing an increase in the amount of insulin released from the beta cells of the islets of Langerhans after eating, before blood glucose levels become elevated. They also slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. As expected, they also inhibit glucagon release from the alpha cells of the Islets of Langerhans. The two main candidate molecules that fulfill criteria for an incretin are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (also known as: glucose-dependent insulinotropic polypeptide or GIP). Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).

GLP-1 (7-36) amide is not very useful for treatment of type 2 diabetes mellitus, since it must be administered by continuous subcutaneous infusion. Several long-lasting analogs having insulinotropic activity have been developed, and two, exenatide (Byetta) and liraglutide (Victoza), have been approved for use in the U.S. The main disadvantage of these GLP-1 analogs is they must be administered by subcutaneous injection.

Another approach is to inhibit the enzyme that inactivates GLP-1 and GIP, DPP-4. Several DPP-4 inhibitors that can be taken orally as a tablet have been developed.

History[edit]

In 1902, Bayliss and Starling proposed that the intestinal mucosa contains a hormone, secretin, that stimulates the exocrine secretion of the pancreas.

However, oral administration of extracts of intestinal mucosa failed to help several patients with type 1 diabetes. In 1932, La Barre proposed the name incretin for a hormone extracted from the upper gut mucosa, which caused hypoglycemia, and proposed a possible therapy for diabetes. In 1939–1940, based on their studies, Leow et al. concluded the existence of incretins was "questionable". No further research in this area was performed for about thirty years.

Recent research[edit]

In 1970, GIP was isolated and sequenced from intestinal mucosa (JC Brown). Originally named gastric inhibitory peptide, GIP was renamed glucose-dependent insulinotropic peptide in 1973 after Brown and Dupre showed GIP stimulates insulin secretion. However, initial research could not establish its utility as a treatment for diabetes. The anglerfish proglucagon peptide was sequenced in 1982 by Lund and co-workers. The human proglucagon gene was cloned in 1983 by G. Bell, et al., and the human proglucagon sequence was subsequently deduced. However, the entire GLP-1 molecule had no effect on insulin levels. Only one specific sequence of GLP-1 was found to have an insulinotropic effect: GLP-1 (7-36) amide. It is rapidly inactivated to GLP-1 (9-36) by DPP-4 with a plasma half-life of only 1–2 minutes. GIP is also rapidly inactivated by DPP-4 to GIP (3-42).

References[edit]

Drucker DJ, Nauck MA (November 2006). "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes". Lancet 368 (9548): 1696–705. doi:10.1016/S0140-6736(06)69705-5. PMID 17098089. Cite uses deprecated parameters (help)
Amori RE, Lau J, Pittas AG (July 2007). "Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis". JAMA 298 (2): 194–206. doi:10.1001/jama.298.2.194. PMID 17622601. Cite uses deprecated parameters (help)

External links[edit]

Glucagon.com - site of Dr D.J. Drucker's laboratory that studies incretins

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 2型糖尿病治療のためのGlucagon-like peptide-1受容体拮抗剤 glucagon like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus
2. 2型糖尿病の治療のためのジペプチジルペプチダーゼ4（DPP-4）阻害剤 dipeptidyl peptidase 4 dpp 4 inhibitors for the treatment of type 2 diabetes mellitus
3. 健常者および疾患を有する患者における消化管ホルモンの概要 overview of gastrointestinal peptides in health and disease
4. 思春期における重度の肥満の外科的マネージメント surgical management of severe obesity in adolescents
5. 腎移植レシピエントにおける移植後新規発症糖尿病（NODAT） new onset diabetes after transplant nodat in renal transplant recipients

English Journal

Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis.

Uchida T1, Oda T2, Matsubara H1, Watanabe A1, Takechi H1, Oshima N1, Sakurai Y3, Kumagai H1.
Renal failure.Ren Fail.2017 Nov;39(1):340-349. doi: 10.1080/0886022X.2017.1279553.
PMID 28118775

Effect of concomitant administration of coenzyme Q10 with sitagliptin on experimentally induced diabetic nephropathy in rats.

Maheshwari R1, Balaraman R1, Sen AK1, Shukla D1, Seth A1.
Renal failure.Ren Fail.2017 Nov;39(1):130-139. doi: 10.1080/0886022X.2016.1254659. Epub 2016 Nov 13.
PMID 27841100

Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from the saliva of the Gila monster.

Alves PL1, Abdalla FMF1, Alponti RF1, Silveira PF2.
Toxicon : official journal of the International Society on Toxinology.Toxicon.2017 Sep 1;135:1-11. doi: 10.1016/j.toxicon.2017.06.001. Epub 2017 Jun 1.
PMID 28579479